Top Markets
#1 Derive Derive +30.93%
#2 Audiera Audiera +14.63%
#3 Cross Cross +11.38%
#4 The Bitcoin Bull The Bitcoin Bull +10.74%
#5 Palladium Network Palladium Network +9.37%
#6 Gama Token Gama Token +9.19%
#7 Biconomy Biconomy +9.00%
#8 Humanity Humanity +8.26%
#9 Geodnet Geodnet +7.98%
#10 Velvet Velvet +7.50%
Coin of the day
Derive Derive
設定
言語
日本
通貨
USD
テーマ
Dogwood Therapeutics, Inc. Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc.

DWTX
株式のランク #35719
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to... Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
株価
$1.84
最終同期: 2026-08-11
時価総額
$3.51M
変化（1日）
0.46%
変化（1年）
-62.71%
国
US
取引 Dogwood Therapeutics, Inc. (DWTX)

カテゴリー

Healthcare
Dogwood Therapeutics, Inc.（DWTX）の利益
2026 時点の利益 TTM: 0
Dogwood Therapeutics, Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Dogwood Therapeutics, Inc. の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE